Codexis total revenue up 23%, product revenue doubles year over year

In California, enzyme engineering company Codexis reported total revenues for Q1 2021 at $18.0 million, an increase of 23% from $14.7 million in Q1 2020. On a segment basis, $14.2 million in revenue was from the Performance Enzymes segment and $3.8 million was from Novel Biotherapeutics.

Product revenues increased 101% to $10.2 million in Q1 (compared to $5.1 million in Q1 2020), driven by enzymes used to manufacture branded pharmaceutical products.

Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics.